Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma

Methods used to control the quality of peptide products depend on the level of development of analytical and bioorganic chemistry, and the level of instrumentation. Peptide identification is a difficult task and largely depends on the complexity of its structure. There does not exist a comprehensive...

Full description

Bibliographic Details
Main Authors: L. M. Krasnykh, V. V. Smirnov, G. V. Ramenskaya, G. F. Vasilenko, I. P. Shilovsky, M. R. Haitov
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2018-09-01
Series:Биопрепараты: Профилактика, диагностика, лечение
Subjects:
tlc
Online Access:https://www.biopreparations.ru/jour/article/view/174
id doaj-a7845fdda29d488a99131ce12be377e1
record_format Article
spelling doaj-a7845fdda29d488a99131ce12be377e12021-07-28T14:03:35ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562018-09-0118318419010.30895/2221-996X-2018-18-3-184-190137Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial AsthmaL. M. Krasnykh0V. V. Smirnov1G. V. Ramenskaya2G. F. Vasilenko3I. P. Shilovsky4M. R. Haitov5Scientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal Products; National Research Centre «Institute of Immunology» of the Federal Medical-Biological Agency of RussiaScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsNational Research Centre «Institute of Immunology» of the Federal Medical-Biological Agency of RussiaNational Research Centre «Institute of Immunology» of the Federal Medical-Biological Agency of RussiaMethods used to control the quality of peptide products depend on the level of development of analytical and bioorganic chemistry, and the level of instrumentation. Peptide identification is a difficult task and largely depends on the complexity of its structure. There does not exist a comprehensive and simple test, except for NMR, which, however, is rather expensive and time-consuming and involves complex data interpretations. Moreover, it does not allow for unambiguous determination of the peptide purity and formula (amino acid composition, sequence, chirality of amino acid residues). For this reason, a combination of methods is often used, including amino acid analysis, TLC/HPLC and mass spectrometry, and, less frequently, sequencing. Current international practice of peptide analysis is to use HPLC in combination with mass spectrometric, mainly tandem (HPLC-MS/MS), detection. According to literature sources the amino acid sequence of linear peptides can be analysed using various enzymes and subsequent identification of proteolysis products by mass spectrometry. This article presents approaches to the development of test methods for analysis of purity and identification testing of a small interfering RNA-based novel medicinal product, which will help standardise and control the quality of the production process.https://www.biopreparations.ru/jour/article/view/174small interfering rna (sirna)bronchial asthmapeptidestandardisationtlchplc-ms/msmaldi-tof
collection DOAJ
language Russian
format Article
sources DOAJ
author L. M. Krasnykh
V. V. Smirnov
G. V. Ramenskaya
G. F. Vasilenko
I. P. Shilovsky
M. R. Haitov
spellingShingle L. M. Krasnykh
V. V. Smirnov
G. V. Ramenskaya
G. F. Vasilenko
I. P. Shilovsky
M. R. Haitov
Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma
Биопрепараты: Профилактика, диагностика, лечение
small interfering rna (sirna)
bronchial asthma
peptide
standardisation
tlc
hplc-ms/ms
maldi-tof
author_facet L. M. Krasnykh
V. V. Smirnov
G. V. Ramenskaya
G. F. Vasilenko
I. P. Shilovsky
M. R. Haitov
author_sort L. M. Krasnykh
title Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma
title_short Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma
title_full Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma
title_fullStr Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma
title_full_unstemmed Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma
title_sort approaches to pharmaceutical analysis of modern peptide and oligonucleotide products as illustrated by a small interfering rna-based novel therapeutic for the treatment of bronchial asthma
publisher Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
series Биопрепараты: Профилактика, диагностика, лечение
issn 2221-996X
2619-1156
publishDate 2018-09-01
description Methods used to control the quality of peptide products depend on the level of development of analytical and bioorganic chemistry, and the level of instrumentation. Peptide identification is a difficult task and largely depends on the complexity of its structure. There does not exist a comprehensive and simple test, except for NMR, which, however, is rather expensive and time-consuming and involves complex data interpretations. Moreover, it does not allow for unambiguous determination of the peptide purity and formula (amino acid composition, sequence, chirality of amino acid residues). For this reason, a combination of methods is often used, including amino acid analysis, TLC/HPLC and mass spectrometry, and, less frequently, sequencing. Current international practice of peptide analysis is to use HPLC in combination with mass spectrometric, mainly tandem (HPLC-MS/MS), detection. According to literature sources the amino acid sequence of linear peptides can be analysed using various enzymes and subsequent identification of proteolysis products by mass spectrometry. This article presents approaches to the development of test methods for analysis of purity and identification testing of a small interfering RNA-based novel medicinal product, which will help standardise and control the quality of the production process.
topic small interfering rna (sirna)
bronchial asthma
peptide
standardisation
tlc
hplc-ms/ms
maldi-tof
url https://www.biopreparations.ru/jour/article/view/174
work_keys_str_mv AT lmkrasnykh approachestopharmaceuticalanalysisofmodernpeptideandoligonucleotideproductsasillustratedbyasmallinterferingrnabasednoveltherapeuticforthetreatmentofbronchialasthma
AT vvsmirnov approachestopharmaceuticalanalysisofmodernpeptideandoligonucleotideproductsasillustratedbyasmallinterferingrnabasednoveltherapeuticforthetreatmentofbronchialasthma
AT gvramenskaya approachestopharmaceuticalanalysisofmodernpeptideandoligonucleotideproductsasillustratedbyasmallinterferingrnabasednoveltherapeuticforthetreatmentofbronchialasthma
AT gfvasilenko approachestopharmaceuticalanalysisofmodernpeptideandoligonucleotideproductsasillustratedbyasmallinterferingrnabasednoveltherapeuticforthetreatmentofbronchialasthma
AT ipshilovsky approachestopharmaceuticalanalysisofmodernpeptideandoligonucleotideproductsasillustratedbyasmallinterferingrnabasednoveltherapeuticforthetreatmentofbronchialasthma
AT mrhaitov approachestopharmaceuticalanalysisofmodernpeptideandoligonucleotideproductsasillustratedbyasmallinterferingrnabasednoveltherapeuticforthetreatmentofbronchialasthma
_version_ 1721268720762880000